• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Pharmaceutical Market
Pharmaceutical News
Pharmaceutical Stocks
  • Pharmaceutical Market
  • Pharmaceutical News
  • Pharmaceutical Stocks
pharmaceutical investing

OpGen Announces Closing of Public Offering of Common Stock

Written by Jocelyn Aspa
|
Mar. 29, 2019 09:03AM PST

OpGen (NASDAQ:OPGN) has announced it has closed its underwritten public offering of nine million shares of its common stock at US$0.60 per share. As quoted in the press release: All of the shares were sold by OpGen. The aggregate gross proceeds to OpGen from the offering, before deducting the underwriting discount and commissions and offering …

OpGen (NASDAQ:OPGN) has announced it has closed its underwritten public offering of nine million shares of its common stock at US$0.60 per share.

As quoted in the press release:

All of the shares were sold by OpGen. The aggregate gross proceeds to OpGen from the offering, before deducting the underwriting discount and commissions and offering expenses, were approximately $5.4 million.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

The shares were issued pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC). A final prospectus was filed with the SEC on March 26, 2019. A copy of the final prospectus relating to the offering, when available, may be obtained by contacting Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019, (212) 813-1010 or by accessing the SEC’s website, www.sec.gov.

Click here to read the full press release.

public offering pharmaceutical investing nasdaq:opgn
The Conversation (0)

Go Deeper

AI Powered
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering

Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

Latest News

Outlook Reports world

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
  • Energy
    • Uranium
    • Oil and Gas
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Industrial Metals
  • Agriculture
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Gaming
    • Cleantech
    • Emerging Tech
Life Science
    • Biotech
    • Cannabis
    • Psychedelics
    • Pharmaceuticals

Featured Pharmaceutical Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES